BUSINESS, PRESENTATION, AND RECENT ACCOUNTING PRONOUNCEMENTS (Details) $ in Thousands, $ in Millions	1 Months Ended
	May 31, 2023 USD ($) shares	Mar. 31, 2024 USD ($) facility	Mar. 28, 2024 USD ($)	Feb. 16, 2024 USD ($)	Feb. 16, 2024 CAD ($)	Dec. 31, 2023 USD ($)
Debt Instrument [Line Items]
Number of pharmaceutical manufacturing facilities | facility		3
Assets held for sale		$ 0				$ 8,020
Disposal Group, Held-for-Sale, Not Discontinued Operations | Oakville, Ontario Former Manufacturing Facility
Debt Instrument [Line Items]
Consideraiton			$ 13,500	$ 14,200	$ 19.2
Common Stock | Public Offering
Debt Instrument [Line Items]
Issuance of common stock (in shares) | shares	2,183,545
Net proceeds after issuance costs	$ 80,600